throbber
ea ::,(cid:173).. en
`!e. :s-
`:, n
`_,m
`!CD
`-· en
`CD U, n -· ~ !. CD
`,, .,,
`u,-,,
`:, Q m .,,
`~~ Im
`CJ> u,a
`
`0
`N
`0
`N
`
`Ill
`~
`
`....
`'< ....
`
`RETINA SPECIALIST PANEL
`
`-<-<-<-<-<-<
`r-<r-<r-<
`-<-<-<-<-<-<
`r-<r-<r-<
`-<r-<r-<r
`-<-<-<-<-<-<
`r-<r-<r-<
`-<r-<r-<r
`-<-<-<-<-<-<
`-~
`
`-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<
`-<r-<r-<r-<r-<►-<►-<►-<r-<r-<r-<r-<r-<►-<r-<r-<r-<►-<►-<
`-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<
`-<r-<r-<r-<r-<r-<r-<r-<r-<r-<r-<r-<r-<►-<r-<r-<r-<r-<r-<
`r-<►-<r-<►-<r-<r-<r-<r-<r-<r-<r-<r-<r-<r-<r-<r-<r-<r-<►
`-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<
`-<r-<r-<r-<r~r~r-<r-<r-<r-<r-<r-<r-<r-<r-<r-<r-<r-<r-<
`r-<r-<r-<r-<r-<r-<r~r-<r-<r-<r-<r-<r~r~r-<r-<r-<r-<r
`-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<-<
`~ ~ ~ ~ ~ ~r~r~r~ r r r r~r~r~ ~r r~
`
`tb NOVARTIS
`
`~
`0
`z
`e;::
`
`~ ..., -C/)
`
`Anti-VEGF PFS Research
`US Retina Specialist insights
`
`May 11, 2020
`
`<O
`00
`~
`--.J
`<O
`0)
`0
`0
`$
`() c
`=i
`0 <
`z
`
`-I < m
`-I m
`0
`;.o
`"U
`0
`-I
`-I
`()
`c... rn
`OJ
`C
`(/)
`
`()
`
`;.o
`0 m
`;.o
`0
`
`-I
`}>
`
`0 z
`;.o s::
`0
`"Tl
`z
`
`(/)
`(/)
`m
`z
`(/)
`C
`OJ
`► r
`-I
`m z
`0
`"Tl
`0 z
`
`()
`(/)
`
`~ z
`0 z
`
`()
`
`Novartis Exhibit 2171.001
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`Objectives & Methodology
`
`Objectives
`
`Novartis is currently preparing for the launch of Beovu in a prefilled syringe (PFS). In order to plan for and
`optimize the Beovu PFS launch, Novartis needs to understand how Retina Specialists (RSs) use and
`perceive the PFS products currently available today.
`
`Methodology
`
`In order to address the research objectives, a 10-m lnute onllne survey was conducted with 50 members
`of the Retina Specialist Panel (4/29/20-511 /20). Completions fell out as shown below:
`
`Reminder: Novartis-supplied sample was used for panel
`recruitment, with quotas on patient volume. Given these and
`other factors, please keep in mind that the panel was not
`designed to be representative of Retina Specialists in general.
`Qualifications of all panel members include:
`Retina Specialist, on Novartis target list
`In practice 2-30 years
`In private practice
`Spend 70%+ of time in direct patient care
`Saw 50+ wet AMD patients in past 3 months
`Currently administers injections to AMD patients
`Mix of specialists in Novartis' 4 behavioraVatlitudinal
`segments
`
`US Retina I Brand Insights
`
`RETINA SPECIALIST PANEL
`
`. 11
`' -
`J!
`-;. ._,\.)_ NOV AIRli I S
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00697 490
`
`Novartis Exhibit 2171.002
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`PFS "Fast Facts"
`
`US Retina I Brand Insights
`
`RETINA SPECIALIST PANEL
`
`f
`~._,.
`~ •• J ~ N OVA'Rli l•S
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00697 491
`
`Novartis Exhibit 2171.003
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00697 492
`
`Novartis Exhibit 2171.004
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`Current PFS Usa e
`
`US Retina I Brand Insights ,.r,.- ~-~ ~e
`.
`
`•~
`
`~
`
`,.,.,
`
`-
`
`'
`
`, ,. •
`
`,.
`
`-
`
`\~~f
`
`RETINA_ SPECIALIST PAN EL
`• ,~ • --•-•'!.,.,...,, ..... •••,.••'-•--..,-.,
`· , • ••~olo,z.
`
`•
`
`~ . J )-NO V)\1R li I S
`
`'
`
`~ . . ._
`
`__ _
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00697 493
`
`Novartis Exhibit 2171.005
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`US Retina I Brand Insights
`
`•~
`
`~fl
`
`,.,.,
`
`,. '
`
`'
`
`,
`
`,. •
`
`,.
`
`RETINA SPECIALIST PANEL
`., •,-.., •-••u-•• .. •• ,, • .,.11a1a, ..... _ • .._o~",
`
`•
`
`I
`
`-
`
`!
`~..._
`,_ . J ) - N OVA'Rli I s
`
`_ .. _ _ _
`
`-
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00697 494
`
`Novartis Exhibit 2171.006
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`PFS Usage Rationale I Selected Quotes
`
`US Retina I Brand Insights
`
`-~
`
`•
`
`··~ ~·--
`
`, )[., .... ~
`
`... ,
`
`... 1,- 1•,p-•,
`
`RETINA SPECIALIST PANEL
`
`!
`~..._
`,_ . J ) - N OVA'Rli I s
`
`_ . . _ _ _
`
`-
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00697 495
`
`Novartis Exhibit 2171.007
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`PFS Satisfaction I
`
`Iv
`LUCENTIS-
`~E
`
`us Retina I Brand Insights ... , ',, ,. ,' .... ,F , • " • " · RETINA s PECI ALI ST PANEL
`
`•~
`
`~,
`
`' • ••~ ~
`
`' .~
`
`"'
`
`· , , •• , ..... u .. ,..., ... .,,.
`
`,{') - N ot A1R li I s
`
`~ .
`
`- • - · -
`
`•
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00697 496
`
`Novartis Exhibit 2171.008
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`PFS Satisfaction
`
`US Retina I Br•nd Insights .... , ·· , ....... ,_.,,,., .•
`
`•~
`
`~,
`
`•
`
`~
`
`••~ ~
`
`'
`
`◄ ~
`
`"'
`
`•
`
`-
`
`,
`
`RETINA SPECIALIST PAN EL
`• ,~ • --•-•'!.,.,...,, ..... •••~••'-•--..,-.,
`• ••~olo,z. -
`
`"':: . J')-N 0t A1R li I S
`
`_ ._
`
`·
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00697 497
`
`Novartis Exhibit 2171.009
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`•11% RS prepare PFS themselves
`
`US Retina I Brand Insights
`
`•~
`
`~•
`
`C
`
`,.,.,
`
`,. '
`
`'
`
`,
`
`,. •
`
`,.
`
`RETINA SPECIALIST PANEL
`., •,-.., •-••u-•• .. •• ,, • .,.11a1a, ..... _ • .._o~",
`
`•
`
`I
`
`-
`
`!
`~..._
`,_ . J ) - N OVA'Rli I s
`
`_ .. _ _ _
`
`-
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00697 498
`
`Novartis Exhibit 2171.0010
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`E lea PFS Attributes
`
`US Retina I Brand Insights
`
`•~
`
`~fl
`
`,.,.,
`
`,. '
`
`'
`
`,
`
`,. •
`
`,.
`
`RETINA SPECIALIST PANEL
`., •,-.., •-••u-•• .. •• ,, • .,.11a1a, ..... _ • .._o~",
`
`•
`
`I
`
`-
`
`!
`~..._
`,_ . J ) - N OVA'Rli I s
`
`_ .. _ _ _
`
`-
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00697 499
`
`Novartis Exhibit 2171.0011
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`Transitioning from Vial to PFS I What went well
`
`•1~ RS state11>at t'le ease of using syringes on pauents lmoadS t>eir 1"e1,nC1>d of presatblno E)'leaPFS
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00697500
`
`Novartis Exhibit 2171.0012
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`•7~ RS s1ate11>at t'le ease of using syringes on pauents lmoadS t>eir ti<et,nCl>d of pruatblno E)'leaPFS
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`
`NOVITC(US)00697501
`
`Novartis Exhibit 2171.0013
`Regeneron v. Novartis, IPR2021-00816
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket